Abstract 812P
Background
Patients with advanced/recurrent EC following disease progression on or after a PBD therapy have a poor prognosis. This descriptive, noninterventional, retrospective cohort study reports on English patient characteristics and survival outcomes, specifically in a population with advanced/recurrent EC that has progressed on or after a first-line (1L) PBD therapy.
Methods
Routine population-level data, from Public Health England’s National Cancer Registration and Analysis Service (NCRAS), was used for this study. Patients diagnosed with advanced/recurrent EC between Jan 1, 2013, and Dec 31, 2018, were included, with data follow-up until Sept 30, 2020. Eligibility was restricted to patients treated with PBD therapy for advanced/recurrent EC. Demographics, baseline characteristics, and treatments received were reported descriptively. Overall survival (OS), time to next treatment (TTNT; a proxy for progression-free survival), and time to treatment discontinuation (TTD) were depicted using Kaplan-Meier methodology. Survival outcomes were measured from the index date (start of 2L therapy).
Results
3415 pts with advanced/recurrent EC who received a 1L PBD were identified. Among these, 29.3% (n=999) received 2L therapy during the study period. Patient demographics for the post-PBD population are in the table. Median OS was 10.3 mo (95%CI, 9.2–11.1 mo), median TTNT was 7.7 mo (95%CI, 7.1–8.2 mo), and median TTD was 3.4 mo (95%CI, 3.2–3.4 mo).
Conclusions
This study provides RW data from England on the patient population, treatment landscape, and survival outcomes of patients with advanced/recurrent EC that progressed on or after a PBD, showing a median survival of <12 months. Thus, there is a critical unmet need for more effective treatments in this population. Table: 812P
| Characteristic | N=999 |
| Median age (range), yDisease stage at primary diagnosis, n (%)RecurrentAdvanced | 66.5 (36.0–84.8)221 (22.1)778 (77.9) |
| Prior lines of therapy in the advanced/recurrent setting, n (%)12 | 992 (99.3)7 (0.7) |
| 2L therapy received, n (%)Carboplatin+paclitaxelCarboplatin+doxorubicinDoxorubicinPaclitaxelCarboplatinOther | 279 (27.9)141 (14.1)130 (13.0)116 (11.6)93 (9.3)240 (24.0) |
Clinical trial identification
Editorial acknowledgement
Writing and editorial support, funded by GlaxoSmithKline (Waltham, MA, USA) and coordinated by Hasan Jamal, MSc, of GlaxoSmithKline, was provided by Nicole Renner, PhD, and Jennifer Robertson, PhD, of Ashfield MedComms, an Ashfield Health company (Middletown, CT, USA).
Legal entity responsible for the study
GlaxoSmithKline.
Funding
GlaxoSmithKline.
Disclosure
K. Heffernan, F.S. Nikitas, U. Shukla, H. Starkie-Camejo: Financial Interests, Personal, Full or part-time Employment: GlaxoSmithKline. C. Knott has declared no conflicts of interest.